Taken together, these xenograft studies strongly support the identification of AURKB as a relevant therapeutic target and justify testing AZD2811NP as a possible therapy for patients with advanced VP-MCC or VN-MCC. This evidence concerns the gene AURKB and Merkel cell skin cancer.